


**SUPPLEMENTARY EUROPEAN SEARCH
REPORT**

 Application number:
EP 20 93 61 34

Classification of the application (IPC):
**A61K 31/7068, A61K 31/7072, A61K 31/7076, A61K 45/06, A61P 31/14,
A61K 31/40, A61K 31/4515, A61K 31/454**
Technical fields searched (IPC):

A61K, A61P

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X	Yamamoto Norio ET AL: "Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro" <i>bioRxiv</i> , 08 April 2020 (2020-04-08) URL: https://www.biorxiv.org/content/10.1101/2020.04.06.026476v1.full.pdf , DOI: 10.1101/2020.04.06.026476 [retrieved on 03 February 2022 (2022-02-03)] XP055887260 * the whole document *	1-6, 8-13, 15
X	Xu Zhijian ET AL: "Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation" <i>bioRxiv</i> , 28 January 2020 (2020-01-28), pages 1-20 URL: https://www.biorxiv.org/content/10.1101/2020.01.27.921627v1.full.pdf , DOI: 10.1101/2020.01.27.921627 [retrieved on 11 May 2021 (2021-05-11)] XP055803842 * the whole document *	1-6, 8-13, 15
X	JEON SANGEUN ET AL: "Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs" <i>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY</i> US 04 May 2020 (2020-05-04), vol. 64, no. 7, DOI: 10.1128/AAC.00819-20, ISSN: 0066-4804, pages e00819-20, XP055825491 * p. 6, 3rd row, 1st compound *	1-15
X	GUL SEREF ET AL: "In silico identification of widely used and well tolerated drugs that may inhibit SARS-Cov-2 3C-like protease and viral RNA-dependent RNA polymerase activities, and may have potential to be directly used in clinical trials" <i>CHEMRXIV</i> , 16 April 2020 (2020-04-16), DOI: 10.26434/CHEMRXIV.12123204.V1, ISSN: 2573-2293, pages 1-49, XP009553837 * abstract; p. 3, last line; p. 41, table S1, 5th compound; table S3 *	1-15

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search The Hague	Date of completion of the search 14 May 2024	Examiner Scheithe, Rupert
------------------------------	---	------------------------------

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 93 61 34

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X,P	<p>Erol C Vatansever: "Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19" <i>bioRxiv</i>, 23 May 2020 (2020-05-23), pages 1-27 URL: https://www.biorxiv.org/content/10.1101/2020.05.23.112235v1.full.pdf , DOI: https://doi.org/10.1101/2020.05.23.112235, XP093161826 * the whole document *</p>	1-15

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search The Hague	Date of completion of the search 14 May 2024	Examiner Scheithe, Rupert
------------------------------	---	------------------------------

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.